Aberrant transcription of FHIT gene in intrahepatic cholangiocellular carcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters

Experimental and Toxicologic Pathology

Volumn 56, Issue 3, 2004, Pages 153-157

  Kitahashi, Tsukasa ^a   Tsujiuchi, Toshifumi ^b,c   Satoh, Kenji ^a   Ohtsuki, Kozo ^a   Konishi, Yoichi ^b   Tsutsumi, Masahiro ^b  

^a KYOTO PREFECTURAL UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

FHIT; Hamster; Intrahepatic cholangiocellular carcinoma; Nitrosamine

Indexed keywords

BIS(2 OXOPROPYL)NITROSAMINE; CHOLINE; ETHIONINE; METHIONINE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; DIET; FEMALE; FRAGILE HISTIDINE TRIAD GENE; GENE; GENE MUTATION; GENETIC TRANSCRIPTION; HAMSTER; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

EID: 10344239918     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2004.08.001     Document Type: Article

References (31)

1. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 1996;35:11529-35.
2. Chen YJ, Chen PH, Chang JG. Aberrant FHIT transcripts in hepatocellular carcinomas. Br J Cancer 1998;77:417-20.
3. Gramantieri L, Chieco P, Tomaso M, Di Masi L, Piscaglia F, Brillanti S, Gaiani S, Valgimigli M, Mazziotti A, Bolondi L. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis. Clin Cancer Res 1999;5:3468-75.
4. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-210.
5. Huang Y, Garrison PN, Barnes LD. Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5′,5‴-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Biochem J 1995;312:925-32.
6. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59:3333-9.
7. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J, Huebner K. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996;56:978-83.
8. Lima CD, Klein MG, Hendrickson WA. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science 1997;278:286-90.
9. Luan X, Shi G, Zohouri M, Paradee W, Smith DI, Decker HJ, Cannizzaro LA. The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma. Oncogene 1997;15:79-86.
10. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990;107:521-7.
11. Mizumoto K, Tsutsumi M, Denda A, Konishi Y. Rapid production of pancreatic carcinoma by initiation with N-nitroso-bis(2-oxopropyl)amine and repeated augmentation pressure in hamsters. J Natl Cancer Inst 1988;80:1564-7.
12. Mizumoto K, Kitazawa S, Ito S, Takashima Y, Tsutsumi M, Denda A, Konishi Y. Cycles of repeated augmentation pressure in rapid production of pancreatic and cholangiocellular carcinomas in hamsters initiated with N-nitroso-bis(2- oxopropyl)amine. Carcinogenesis 1989;10:1457-9.
13. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56:3173-9.
14. Ohashi K, Nakajima Y, Tsutsumi M, Kanehiro H, Fukuoka T, Hisanaga M, Taki J, Nakae D, Konishi Y, Nakano H. Clinical characteristics and proliferating activity of intrahepatic cholangiocarcinoma. J Gastroenterol Hepatol 1994;9:442-6.
15. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, Konishi Y, Nakano H. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995; 109:1612-7.
16. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
17. Okita S, Tsutsumi M, Onji M, Konishi Y. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol Carcinog 1995;13:266-71.
18. Simon B, Bartsch D, Barth P, Prasnikar N, Munch K, Blum A, Arnold R, Goke B. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998;58:1583-7.
19. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, Gregorio L, De Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996:85:17-26.
20. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, Goldstraw P, Huebner K, Croce CM, Pierotti MA. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57:5207-12.
21. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58:5032-7.
22. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-9.
23. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-83.
24. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, Mao L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999;59:4798-803.
25. Tsujiuchi T, Sasaki Y, Murata N, Tsutsumi M, Konishi Y, Nakae D. FHIT alterations in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl) amine in rats. Carcinogenesis 2001;22:2017-22.
26. Tsujiuchi T, Sasaki Y, Kubozoe T, Tsutsumi M, Konishi Y, Nakae D. Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol Carcinog 2002;34:19-24.
27. Tsujiuchi T, Sasaki Y, Kubozoe T, Konishi Y, Tsutsumi M. Alterations in the Fhit gene in pancreatic duct adenocarcinomas induced by N-nitrosobis(2- oxopropyl)amine in hamsters. Mol Carcinog 2003a;36:60-6.
28. Tsujiuchi T, Sasaki Y, Oka Y, Konishi Y, Tsutsumi M. Fhit gene alterations in hepatocarcinogenesis induced by a choline-deficient L-amino acid-defined diet in rats. Mol Carcinog 2003b;36:147-52.
29. Tsutsumi M, Kondoh S, Noguchi O, Horiguchi K, Kobayashi E, Okita S, Ohashi K, Honoki K, Tsujiuchi T, Konishi Y. K-ras gene mutation in early ductal lesions induced in a rapid production model for pancreatic carcinomas in Syrian hamsters. Jpn J Cancer Res 1993a;84:1101-5.
30. Tsutsumi M, Murakami Y, Kondoh S, Tsujiuchi T, Hohnoki K, Horiguchi K, Noguchi O, Kobayashi E, Okita S, Sekiya T, Konishi Y. Comparison of K-ras oncogene activation in pancreatic duct carcinomas and cholangiocarcinomas induced in hamster by N-nitrosobis(2-hydroxyoplopyl)amine. Jpn J Cancer Res 1993b;84:956-60.
31. Yamamoto J, Kosuge T, Takayama T, Shimada K, Makuuchi M, Yoshida J, Sakamoto M, Hirohashi S, Yamasaki S, Hasegawa H. Surgical treatment of intrahepatic cholangio-carcinoma: four patients surviving more than five years. Surgery 1992;622:617-22.